Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

The Liver-α-Cell Axis and Type 2 Diabetes

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. At the crossroads of fate - somatic cell lineage specification in the fetal gonad

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Cytokines and beta-cell biology: from concept to clinical translation

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Effect of the incretin hormones on the endocrine pancreas in end-stage renal disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Investigating Intestinal Glucagon after Roux-en-Y Gastric Bypass Surgery

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Methods and guidelines for measurement of glucagon in plasma

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Glucagon Receptor Signaling and Glucagon Resistance

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  • Nicolai J Wewer Albrechtsen
  • Jens Pedersen
  • Katrine D Galsgaard
  • Marie Winther-Sørensen
  • Malte P Suppli
  • Lina Janah
  • Jesper Gromada
  • Hendrik Vilstrup
  • Filip K Knop
  • Jens J Holst
Vis graf over relationer

Both type 2 diabetes (T2D) and nonalcoholic fatty liver disease (NAFLD) strongly associate with increasing body mass index, and together these metabolic diseases affect millions of individuals. In patients with T2D, increased secretion of glucagon (hyperglucagonemia) contributes to diabetic hyperglycemia as proven by the significant lowering of fasting plasma glucose levels following glucagon receptor antagonist administration. Emerging data now indicate that the elevated plasma concentrations of glucagon may also be associated with hepatic steatosis and not necessarily with the presence or absence of T2D. Thus, fatty liver disease, most often secondary to overeating, may result in impaired amino acid turnover, leading to increased plasma concentrations of certain glucagonotropic amino acids (e.g., alanine). This, in turn, causes increased glucagon secretion that may help to restore amino acid turnover and ureagenesis, but it may eventually also lead to increased hepatic glucose production, a hallmark of T2D. Early experimental findings support the hypothesis that hepatic steatosis impairs glucagon's actions on amino acid turnover and ureagenesis. Hepatic steatosis also impairs hepatic insulin sensitivity and clearance that, together with hyperglycemia and hyperaminoacidemia, lead to peripheral hyperinsulinemia; systemic hyperinsulinemia may itself contribute to worsen peripheral insulin resistance. Additionally, obesity is accompanied by an impaired incretin effect, causing meal-related glucose intolerance. Lipid-induced impairment of hepatic sensitivity, not only to insulin but potentially also to glucagon, resulting in both hyperinsulinemia and hyperglucagonemia, may therefore contribute to the development of T2D at least in a subset of individuals with NAFLD.

OriginalsprogEngelsk
TidsskriftEndocrine Reviews
Vol/bind40
Udgave nummer5
Sider (fra-til)1353-1366
Antal sider14
ISSN0163-769X
DOI
StatusUdgivet - 1 okt. 2019

Bibliografisk note

Copyright © 2019 Endocrine Society.

ID: 56951217